Evidence map›Paper›PMID 32473124›Full record

ArticleThe Lancet. Respiratory medicine2020

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.

Sharon E Fox, Aibek Akmatbekov, Jack L Harbert, Guang Li, J Quincy Brown, Richard S Vander Heide

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in The Lancet. Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 924 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
924citing papers in PubMed, 4 pooled it
33.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04640038 phase3completednot on this map

Contrast Enhanced Ultrasound (CEUS) Detection of Microvascular Perfusion Impairment in COVID-19 Pediatric Patients

TypeinterventionalSponsorChildren's Hospital of PhiladelphiaRan2020 to 2021Enrolled4ConditionsCovid19, Multisystem Inflammatory Syndrome in Children (MIS-C)ArmsSulfur hexafluoride lipid-type A microspheres
NCT04771000 phase2terminatednot on this mapstarted 2021, after this paper: background citation

A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19

TypeinterventionalSponsorNoorik Biopharmaceuticals AGRan2021 to 2023Enrolled88ConditionsCovid19, HypoxemiaArmsAmbrisentan, Placebo
3 · Its place in the literature

Who cites it

924 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,402 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

864 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sharon E FoxDepartment of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Pathology and Laboratory Medicine Service, Southeast Louisiana Veterans Healthcare System, New Orleans, LA, USA. Electronic address: sfox3@lsuhsc.edu.
Aibek AkmatbekovDepartment of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Jack L HarbertDepartment of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Guang LiDepartment of Biomedical Engineering, Tulane University, New Orleans, LA, USA.
J Quincy BrownDepartment of Biomedical Engineering, Tulane University, New Orleans, LA, USA.
Richard S Vander HeideDepartment of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA, USA. Electronic address: rvand3@lsuhsc.edu.
Louisiana State University Health Sciences Center New Orleans · USTulane University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly across the USA, causing extensive morbidity and mortality, particularly in the African American community. Autopsy can considerably contribute to our understanding of many disease processes and could provide crucial information to guide management of patients with coronavirus disease 2019 (COVID-19). We report on the relevant cardiopulmonary findings in, to our knowledge, the first autopsy series of ten African American decedents, with the cause of death attributed to COVID-19.

methodsAutopsies were performed on ten African American decedents aged 44-78 years with cause of death attributed to COVID-19, reflective of the dominant demographic of deaths following COVID-19 diagnosis in New Orleans. Autopsies were done with consent of the decedents' next of kin. Pulmonary and cardiac features were examined, with relevant immunostains to characterise the inflammatory response, and RNA labelling and electron microscopy on representative sections.

findingsImportant findings include the presence of thrombosis and microangiopathy in the small vessels and capillaries of the lungs, with associated haemorrhage, that significantly contributed to death. Features of diffuse alveolar damage, including hyaline membranes, were present, even in patients who had not been ventilated. Cardiac findings included individual cell necrosis without lymphocytic myocarditis. There was no evidence of secondary pulmonary infection by microorganisms.

interpretationWe identify key pathological states, including thrombotic and microangiopathic pathology in the lungs, that contributed to death in patients with severe COVID-19 and decompensation in this demographic. Management of these patients should include treatment to target these pathological mechanisms.

fundingNone.

Indexed as

Black or African AmericanAdultAgedAutopsyBetacoronavirusCoronavirus InfectionsCOVID-19FemaleHumansLungMaleMiddle AgedMyocardiumNew OrleansPandemicsPneumonia, Viral

Identifiers

PMID32473124
PMCPMC7255143
OpenAlexW3031456278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.